<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449693</url>
  </required_header>
  <id_info>
    <org_study_id>HIM-2017-085</org_study_id>
    <nct_id>NCT03449693</nct_id>
  </id_info>
  <brief_title>Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia</brief_title>
  <official_title>Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia in Pediatric Oncology Patients Treated With Cisplatin-Based Chemotherapy: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional Autonoma de Mexico</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial. Open label. Parallel Groups. The purpose of the study is to determine the
      efficacy of oral supplementation with magnesium oxide to reduce febrile neutropenia episodes
      in pediatric oncology patients treated with cisplatin-based chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Febrile neutropenia (FN) is a worrying outcome in children receiving chemotherapy because it
      increments the risk of major complications, reduces quality of life and increments treatment
      costs. Moreover, it is the most common diagnosis in pediatric oncology patients that enter
      emergency rooms and the second most important cause of hospitalization, just behind
      hospitalization for administration of chemotherapy.

      In Mexico, incidence of FN is of 62% of children with solid tumors treated with
      cisplatin-based chemotherapy (CBC). Cisplatin is one of the most nephrotoxic drugs being used
      in clinical settlements. The assessment of nephrotoxicity is made with the manifestation of
      tubular damage that causes electrolyte losses, specially of magnesium. Recently, our
      investigation group reported that there is an association of hypomagnesemia and the
      apparition of FN. This association has a biologic explanation in the fact that magnesium is a
      necessary cofactor for the neutrophil's diapedesis and the activation of complement cascade.
      To our knowledge, the role of magnesium supplementation has not been explored. With this
      evidence in mind, the investigators wondered if oral supplementation with magnesium will
      reduce FN episodes in pediatric oncology patients treated with CBC.

      Objective: Determine the efficacy of oral supplementation with magnesium to reduce FN
      episodes in pediatric oncology patients treated with CBC.

      Hypothesis: Previous clinical trials made in adult population have reported that
      supplementation with magnesium salts reduce episodes of hypomagnesemia in between 13 and 50%.
      Thus, oral supplementation with magnesium oxide will reduce 20% of FN episodes in pediatric
      oncology patients treated with CBC.

      Materials and Methods: Randomized Clinical Trial, open-label, parallel groups of children
      over the age of nine with solid tumors treated with CBC at the Haemato-Oncology Department of
      the Hospital Infantil de México. To prove the hypothesis, it is required to randomize 107 CBC
      cycles to the intervention group and 107 CBC cycles to the control group. The sample size
      calculation was made by using the two proportions formula. Randomize of children will be made
      when they receive CBC indication. Patients assigned to the intervention group will receive
      institutional attention protocol plus a bottle of magnesium oxide, at the moment of
      hospitalization discharge. Patients assigned to the control group will receive only
      institutional attention protocol. The follow-up of patients will be made until an episode of
      FN appears or until the patient comes back for another CBC cycle. FN assessment will be
      measured with a unique temperature &gt;38.3°C or a sustained temperature &gt;38°C over the course
      of an hour plus a count of neutrophils under 1000 cells/mm3. The efficacy of oral
      supplementation with magnesium oxide will be determined by a Relative Risks calculation with
      confidence interval of 95% (CI95%). Moreover, Absolute Risk Reduction will be calculated, as
      well as Necessary Number to Treat. To adjust the principal variable a multivariate analysis
      will be made with a multiple logistic regression. The analysis will be made by protocol and
      by intention to treat.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups: Intervention group and control group. The intervention group will receive institutional care protocol plus oral supplementation with magnesium. The control group will receive institutional care protocol only.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Febrile Neutropenia</measure>
    <time_frame>After randomization until day 30</time_frame>
    <description>Unique temperature &gt;38.3°C or sustained temperature &gt;38°C over the course of an hour, and a total count of neutrophils &lt;1000 cells/mm3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time passed from cisplatin-based chemotherapy until the apparition of febrile neutropenia</measure>
    <time_frame>After randomization until day 30</time_frame>
    <description>Total of days passed from the randomization up to the apparition of febrile neutropenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of Oral Supplementation with Magnesium</measure>
    <time_frame>Evaluate the apparition of adverse effects of oral supplement of magnesium oxide Time Frame: After randomization until day 30</time_frame>
    <description>Evaluate the apparition of adverse effects of oral supplement of magnesium oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypomagnesemia</measure>
    <time_frame>After randomization until day 30</time_frame>
    <description>Serum magnesium &lt;1.6 mg/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">214</enrollment>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Magnesium Oxide Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium Oxide 250 mg tablet, daily for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Supplement</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium Oxide Supplement</intervention_name>
    <description>Magnesium Oxide tablet</description>
    <arm_group_label>Magnesium Oxide Supplement</arm_group_label>
    <other_name>M250</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients &gt; 9 years old

          -  Pediatric patients with solid tumors treated with cisplatin-based chemotherapy

          -  Signing of Informed Consent from the parents

          -  Signing of Informed Assent from the children

        Non-inclusion Criteria:

          -  Patients whose parents do not sign the Informed Consent

          -  Patients with magnesium losing tubulopathy

          -  Patients with hypomagnesemia previous to the cisplatin-based chemotherapy

        Exclusion Criteria:

        - Patients whose parents retire the Informed Consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osvaldo D Castelán, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Nacional Autónoma de México. Facultad de Estudios Superiores Zaragoza</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel A Palomo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Infantil de México Dr. Federico Gómez</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victoria E Barrios, QFB</last_name>
    <phone>+52 1 2291290208</phone>
    <email>victoria.barrios@cinvestav.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Infantil de Mexico Dr. Federico Gomez</name>
      <address>
        <city>Cuauhtémoc</city>
        <state>Ciudad De México</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria E Barrios, QFB</last_name>
      <phone>+52 1 2291290208</phone>
      <email>victoria.barrios@cinvestav.mx</email>
    </contact>
    <contact_backup>
      <last_name>Miguel A Palomo, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Freifeld AG, Pizzo PA. The outpatient management of febrile neutropenia in cancer patients. Oncology (Williston Park). 1996 Apr;10(4):599-606, 611-2; discussion 615-6. Review.</citation>
    <PMID>8723296</PMID>
  </reference>
  <reference>
    <citation>Castagnola E, Paola D, Giacchino R, Rossi R, Viscoli C. Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer. 1998 Nov;6(6):524-8.</citation>
    <PMID>9833301</PMID>
  </reference>
  <reference>
    <citation>Mueller EL, Sabbatini A, Gebremariam A, Mody R, Sung L, Macy ML. Why pediatric patients with cancer visit the emergency department: United States, 2006-2010. Pediatr Blood Cancer. 2015 Mar;62(3):490-5. doi: 10.1002/pbc.25288. Epub 2014 Oct 24. Erratum in: Pediatr Blood Cancer. 2018 Apr;65(4):.</citation>
    <PMID>25345994</PMID>
  </reference>
  <reference>
    <citation>Klaassen RJ, Goodman TR, Pham B, Doyle JJ. &quot;Low-risk&quot; prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol. 2000 Mar;18(5):1012-9.</citation>
    <PMID>10694551</PMID>
  </reference>
  <reference>
    <citation>Castelán-Martínez OD, Rodríguez-Islas F, Vargas-Neri JL, Palomo-Colli MA, López-Aguilar E, Clark P, Castañeda-Hernández G, Rivas-Ruiz R. Risk Factors for Febrile Neutropenia in Children With Solid Tumors Treated With Cisplatin-based Chemotherapy. J Pediatr Hematol Oncol. 2016 Apr;38(3):191-6. doi: 10.1097/MPH.0000000000000515.</citation>
    <PMID>26907640</PMID>
  </reference>
  <reference>
    <citation>Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999 Feb;25(1):47-58. Review.</citation>
    <PMID>10212589</PMID>
  </reference>
  <reference>
    <citation>Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bökenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev. 2013 Oct 8;(10):CD008944. doi: 10.1002/14651858.CD008944.pub2. Review.</citation>
    <PMID>24101439</PMID>
  </reference>
  <reference>
    <citation>Willox JC, McAllister EJ, Sangster G, Kaye SB. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer. 1986 Jul;54(1):19-23.</citation>
    <PMID>3524645</PMID>
  </reference>
  <reference>
    <citation>Martin M, Diaz-Rubio E, Casado A, López Vega JM, Sastre J, Almenarez J. Intravenous and oral magnesium supplementations in the prophylaxis of cisplatin-induced hypomagnesemia. Results of a controlled trial. Am J Clin Oncol. 1992 Aug;15(4):348-51.</citation>
    <PMID>1514533</PMID>
  </reference>
  <reference>
    <citation>Zarif Yeganeh M, Vakili M, Shahriari-Ahmadi A, Nojomi M. Effect of Oral Magnesium Oxide Supplementation on Cisplatin-Induced Hypomagnesemia in Cancer Patients: A Randomized Controlled Trial. Iran J Public Health. 2016 Jan;45(1):54-62.</citation>
    <PMID>27057522</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Nacional Autonoma de Mexico</investigator_affiliation>
    <investigator_full_name>Osvaldo Daniel Castelan Martinez</investigator_full_name>
    <investigator_title>Full Time Associate Professor C</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

